[Form 4] Beam Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

John M. Evans, Beam Therapeutics Inc. CEO and director, reported option exercises and sales in early October 2025 under a Rule 10b5-1 plan. On 10/01/2025 and 10/02/2025 he exercised two stock option tranches at a $0.67 strike for 25,000 shares each and sold corresponding blocks of 25,000 shares on each date. The sales were executed as multiple transactions at weighted average prices of approximately $24.5062 (range $24.14–$24.92) and $24.6267 (range $24.22–$25.05). Following the reported acquisitions, Mr. Evans beneficially owned 1,011,667 shares directly and 103,000 shares indirectly via the John M. Evans, III 2018 Irrevocable Trust. The Form 4 notes the option grants dated 05/08/2018 with portions still exercisable and expiring on 05/08/2028, and that the trades were made pursuant to a trading plan adopted on 05/16/2025.

Positive

• Transactions executed under a Rule 10b5-1 plan adopted on 05/16/2025, indicating pre-planned trading
• Options exercised at a low strike of $0.67, converting long-term compensation into shares
• Beneficial ownership disclosed explicitly: 1,011,667 shares direct and 103,000 indirect

Negative

• Insider sold a total of 50,000 shares (two blocks of 25,000), which is a material insider disposition
• Sales executed across price ranges ($24.14–$25.05), requiring weighted-average reporting rather than single price visibility

Insights

Corporate Governance Specialist

TL;DR: Insider exercised low-strike options and sold shares under a documented Rule 10b5-1 plan.

The Form 4 shows the CEO, John M. Evans, using a 10b5-1 trading plan adopted 05/16/2025 to effect exercises and sales on 10/01/2025–10/02/2025. Using an established plan can reduce concerns about timing and selective disclosure because trades follow a pre-set program rather than opportunistic timing.

The filing discloses total direct beneficial ownership of 1,011,667 shares and 103,000 shares held indirectly via a trust, which are concrete share counts investors can use to track insider stake.

Equity Compensation Analyst

TL;DR: CEO exercised options at a $0.67 strike and sold shares at ~$24.5, realizing material gross proceeds per option.

The report shows two option exercises (each for 25,000 shares) with an exercise price of $0.67 and corresponding sales of those shares at weighted average prices of $24.5062 and $24.6267. These transactions convert equity compensation from underwater strike to liquid shares and realize the intrinsic value equal to the sale price minus the $0.67 strike.

The options referenced were granted 05/08/2018 and retain exercisable portions expiring on 05/08/2028, which is relevant for potential future option exercises and dilution considerations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Evans John M.

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M(1)		25,000	A	$0.67	1,011,667(2)	D
Common Stock	10/01/2025		S(1)		25,000	D	$24.5062(3)	986,667	D
Common Stock	10/02/2025		M(1)		25,000	A	$0.67	1,011,667	D
Common Stock	10/02/2025		S(1)		25,000	D	$24.6267(4)	986,667	D
Common Stock								103,000	I	By John M. Evans, III 2018 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.67	10/01/2025		M(1)			25,000	(5)	05/08/2028	Common Stock	25,000	$0	44,336	D
Stock Option (Right to Buy)	$0.67	10/02/2025		M(1)			25,000	(5)	05/08/2028	Common Stock	25,000	$0	19,336	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

2. Includes 418 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.14 to $24.92, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.22 to $25.05, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

5. On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022.

	By: /s/ Christine Bellon, Attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beam Therapeutics (BEAM) insider John M. Evans report on the Form 4?

He reported exercising stock options at a $0.67 strike and selling shares on 10/01/2025 and 10/02/2025 under a Rule 10b5-1 plan.

How many shares did John M. Evans sell and at what prices?

He sold two blocks of 25,000 shares each (total 50,000). Weighted average sale prices were approximately $24.5062 and $24.6267, with reported ranges of $24.14–$24.92 and $24.22–$25.05.

How many shares does John M. Evans beneficially own after these transactions?

The Form 4 reports 1,011,667 shares beneficially owned directly and 103,000 shares indirectly via the John M. Evans, III 2018 Irrevocable Trust.

When were the options granted and when do they expire?

The options were granted on 05/08/2018 and portions remain exercisable with an expiration date of 05/08/2028.

Were the trades part of a pre-established trading plan?

Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on 05/16/2025.